Drug profile · INN
tiotropium bromide
SPIRIVA RESPIMAT
tiotropium bromide (SPIRIVA RESPIMAT) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — tiotropium bromide
- US status
- approved
- Class
- —
- Route
- INHALATION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
tiotropium bromide (SPIRIVA RESPIMAT) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tiotropium bromide?
tiotropium bromide (SPIRIVA RESPIMAT) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for tiotropium bromide?
SPIRIVA RESPIMAT is a marketed brand name for tiotropium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tiotropium bromide?
tiotropium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.